The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.
This is a prospective observational cohort study in 8-10 cardiac centres across Europe. We will recruit patients presenting with acute myocardial infarction (AMI) and CS who are supported medically (n=100); with extracorporeal membrane oxygenation (n=50); and with the Impella Device (n=50). We will also enrol patients who present with either AMI and no evidence of CS (n=50) or CS due to non-ischaemic pathologies (e.g. myocarditis: n=50) as comparators. The recruitment target is 300 patients.
Study Type
OBSERVATIONAL
Enrollment
300
Blood sampling and clinical data collection
Barts Health NHS trust
London, United Kingdom
RECRUITINGThe primary aim is to better understand the heterogeneity of the immune consequences and treatment responses in CS through identification of transcriptomic sub-phenotypes and their association with in-hospital mortality
This will be achieved through bloods sample collection, analysis and linked to the patient's clinical diagnosis and outcome.
Time frame: through study completion, an average of 5 days
Identify transcriptomic (and chemokine/cytokine) signatures at presentation that elucidate the pathobiology of CS and examine their subsequent evolution.
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Correlate recently identified clinical phenotypes of CS with transcriptomic and inflammatory mediator signatures.
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Identify transcriptomic and chemokine/cytokine signatures at presentation that improve prognostic accuracy in patients with CS
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Investigate inter-individual heterogeneity in the dynamic transcriptomic response to CS through an eQTL mapping approach and identify context- specific regulatory genetic variants involving gene networks central to the pathogenesis of CS.
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Identity novel therapeutic targets that might modulate the dysfunctional immune response to CS - "drug discovery"
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Determine the extent to which the signatures and drivers of a dysfunctional immune response in CS are shared with other critical illness syndromes.
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days